SRPT - Sarepta's Elevidys now approved for non-ambulatory Duchenne muscular dystrophy
2024-06-20 17:31:25 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics: Navigating Elevidys Upside Potential
- Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
- Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
- Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy
- RBC Capital cuts Sarepta to sector perform ahead of FDA decision